Ebola Virus Entry Inhibitors

Ruikun Du; Qinghua Cui; Michael Caffrey; Lijun Rong

doi:10.1007/978-981-16-8702-0_10

Ebola Virus Entry Inhibitors

Adv Exp Med Biol. 2022:1366:155-170. doi: 10.1007/978-981-16-8702-0_10.

Authors

Ruikun Du¹, Qinghua Cui¹, Michael Caffrey², Lijun Rong³

Affiliations

¹ Shandong University of Traditional Chinese Medicine, Jinan, China.
² Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
³ Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA. Lijun@uic.edu.

PMID: 35412140
DOI: 10.1007/978-981-16-8702-0_10

Abstract

Ebola virus (EBOV) is one of the most deadliest agents already known, causing periodic epidemic of a severe hemorrhagic fever disease in Africa. Although two monoclonal antibody (mAb) drugs have recently received approval in the USA, additional therapeutics are still needed to combat potential outbreaks of resistance variants and other closely related ebola viruses. In this chapter, we describe the current understanding of the EBOV entry process and summarize the approaches, strategies, and advances in discovery and development of EBOV entry inhibitors, including therapeutic antibodies, peptides, small molecules, natural products, and other chemical structures.

Keywords: Drug repurposing; Ebola virus; Entry inhibitor; Small molecule; Therapeutic mAb.

MeSH terms

Antibodies, Monoclonal / therapeutic use
Disease Outbreaks
Ebolavirus*
Hemorrhagic Fever, Ebola* / drug therapy
Humans
Virus Internalization

Substances

Antibodies, Monoclonal